Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Ticker SymbolSMLR
Company nameSemler Scientific Inc
IPO dateFeb 27, 2014
CEOMurphy Chutorian (Douglas)
Number of employees79
Security typeOrdinary Share
Fiscal year-endFeb 27
Address51 E Campbell Ave
CityCAMPBELL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code95008
Phone18777744211
Websitehttps://www.semlerscientific.com/
Ticker SymbolSMLR
IPO dateFeb 27, 2014
CEOMurphy Chutorian (Douglas)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data